




PHARMACEUTICAL 2021

**REGENERX
BIOPHARMACEUTICALS INC**
Rank 375 of 402





PHARMACEUTICAL 2021

REGENERX BIOPHARMACEUTICALS INC Rank 375 of 402

The relative strengths and weaknesses of REGENERX BIOPHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of REGENERX BIOPHARMACEUTICALS INC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 33% points. The greatest weakness of REGENERX BIOPHARMACEUTICALS INC is the variable Assets, Current, reducing the Economic Capital Ratio by 186% points.

The company's Economic Capital Ratio, given in the ranking table, is -325%, being 372% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	478
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	400
Liabilities, Non-Current	2,052
Other Assets	74
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	924
Other Net Income	-229
Other Revenues	77
Property and Equipment	0
Research and Development	4.9
Selling, General and Administrative Expense	1,366

Output Variable	Value in 1000 USD
Assets	552
Liabilities	3,376
Expenses	1,371
Revenues	77
Stockholders Equity	-2,824
Net Income	-1,523
Comprehensive Net Income	-1,523
Economic Capital Ratio	-325%